Although ponatinib was given accelerated approval by the FDA, it was withdrawn based on evidence of serious thrombotic adverse events.
{{{error}}}
{{error}}
{{{ form.title }}}
*Required
By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions.